Béatrice Nawrocki-Raby

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 6

Top Topics

Tyrosine Kinase

Small Cell Lung Cancer

Epidermal Growth Factor Receptor

Papillary Thyroid

Top Venues

Life (Basel, Switzerland)

The Journal of pathology

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Emma Loeffler, Julien Ancel, Véronique Dalstein, Gaëtan Deslée, Myriam Polette, Béatrice Nawrocki-Raby
HER2 Alterations in Non-Small Cell Lung Cancer: Biologico-Clinical Consequences and Interest in Therapeutic Strategies. Life (Basel, Switzerland) 14 (1) (2023)
Emma Loeffler, Julien Ancel, Véronique Dalstein, Gaëtan Deslée, Myriam Polette, Béatrice Nawrocki-Raby
HER2 Alterations in Non-Small Cell Lung Cancer: Biologico-Clinical Consequences and Interest in Therapeutic Strategies. Life (Basel, Switzerland) 14 (1) (2023)
Emma Loeffler, Julien Ancel, Véronique Dalstein, Gaëtan Deslée, Myriam Polette, Béatrice Nawrocki-Raby
HER2 Alterations in Non-Small Cell Lung Cancer: Biologico-Clinical Consequences and Interest in Therapeutic Strategies. Life (Basel, Switzerland) 14 (1) (2023)
Anda Huna, Béatrice Nawrocki-Raby, Teresita Padilla-Benavides, Julie Gavard, Sylvie Coscoy, David Bernard, Mathieu Boissan
Loss of the Metastasis Suppressor NME1, But Not of Its Highly Related Isoform NME2, Induces a Hybrid Epithelial-Mesenchymal State in Cancer Cells. International journal of molecular sciences 22 (7) (2021)
Julien Ancel, Jeanne-Marie Perotin, Maxime Dewolf, Claire Launois, Pauline Mulette, Béatrice Nawrocki-Raby, Véronique Dalstein, Christine Gilles, Gaëtan Deslée, Myriam Polette, Valérian Dormoy
Hypoxia in Lung Cancer Management: A Translational Approach. Cancers 13 (14) (2021)
Jordan Da Silva, Amina Jouida, Julien Ancel, Véronique Dalstein, Julie Routhier, Gonzague Delepine, Jérôme Cutrona, Antoine Jonquet, Maxime Dewolf, Philippe Birembaut, Gaëtan Deslée, Myriam Polette, Béatrice Nawrocki-Raby
FHITlow /pHER2high signature in non-small cell lung cancer is predictive of anti-HER2 molecule efficacy. The Journal of pathology 251 (2) (2020)